The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 1, 2006, Pages 1-8

  Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DOCETAXEL; LOW MOLECULAR WEIGHT HEPARIN; PROADIFEN; THALIDOMIDE;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER THERAPY; CLINICAL TRIAL; CONSTIPATION; DOSE RESPONSE; DRUG APPROVAL; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRY EYE; DRY SKIN; DYSPNEA; EDEMA; ERYTHEMA NODOSUM LEPROSUM; FATIGUE; HUMAN; LEPROSY; MYALGIA; NEUTROPENIA; NOTE; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SEDATION; SIDE EFFECT; STROKE; TERATOGENICITY; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

ANDROGENS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TAXOIDS; THALIDOMIDE;

EID: 30344445990     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.09.006     Document Type: Note

References (27)

1. J. Folkman Tumor angiogenesis a possible control point in tumor growth Ann Intern Med 82 1975 96 100
2. Food and Drug Administration FDA approves first angiogenesis inhibitor to treat colorectal cancer 2004 FDA News Feb 26. Available from: URL: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01027.html.
3. D.M. McDonald, B.A. Teicher, W. Stetler-Stevenson, S.S. Ng, W.D. Figg, J. Folkman Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring J Immunother 27 2004 161 175
4. M. Cox, Y. Liu, W.D. Figg Antiangiogenesis in prostate cancer Cancer Ther 2004 121 129
5. G.R. Macpherson, S.S. Ng, N.J. Lakhani, D.K. Price, J. Venitz, W.D. Figg Antiangiogenesis therapeutic strategies in prostate cancer Cancer Metastasis Rev 21 2002 93 106
6. W.D. Figg, E.A. Kruger, D.K. Price, S. Kim, W.D. Dahut Inhibition of angiogenesis treatment options for patients with metastatic prostate cancer Invest New Drugs 20 2002 183 194
7. M.E. Franks, G.R. Macpherson, W.D. Figg Thalidomide Lancet 363 2004 1802 1811
8. W.G. McBride Teratogenic action of thalidomide [letter] Lancet 1 1978 1362
9. Food and Drug Administration FDA approves thalidomide for Hansen's disease side effect, imposes unprecedented restrictions on distribution 1998 FDA Talk Paper Jul 16. Available from: URL: http://www.fda.gov/bbs/topics/answers/ ans00887.html.
10. R.J. D'Amato, M.S. Loughnan, E. Flynn, J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 91 1994 4082 4085
11. K.S. Bauer, S.C. Dixon, W.D. Figg Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 55 1998 1827 1834
12. Y. Ando, E. Fuse, W.D. Figg Thalidomide metabolism by the CYP2C subfamily Clin Cancer Res 8 2002 1964 1973
13. E.A. Kruger, P.H. Duray, D.K. Price, J.M. Pluda, W.D. Figg Approaches to preclinical screening of antiangiogenic agents Semin Oncol 28 2001 570 576
14. D.K. Price, Y. Ando, E.A. Kruger, M. Weiss, W.D. Figg 5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis Ther Drug Monit 24 2002 104 110
15. W.D. Figg, W. Dahut, P. Duray, M. Hamilton, A. Tompkins, S.M. Steinberg A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 2001 1888 1893
16. D.P. Petrylak Chemotherapy for advanced hormone refractory prostate cancer Urology 54 Suppl 1999 30 35
17. D.P. Petrylak Docetaxel (Taxotere) in hormone-refractory prostate cancer Semin Oncol 27 Suppl 3 2000 24 29
18. D.P. Petrylak Combination therapy in hormone-refractory prostate cancer Curr Oncol Rep 3 2001 417
19. D.P. Petrylak Chemotherapy for androgen-independent prostate cancer Semin Urol Oncol 20 Suppl 1 2002 31 35
20. D.P. Petrylak, R. Macarthur, J. O'Connor, G. Shelton, A. Weitzman, T. Judge Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer Semin Oncol 26 Suppl 17 1999 28 33
21. D.P. Petrylak, R.B. Macarthur, J. O'Connor, G. Shelton, T. Judge, J. Balog Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer J Clin Oncol 17 1999 958 967
22. B.A. Teicher, E.A. Sotomayor, Z.D. Huang Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease Cancer Res 52 1992 6702 6704
23. W.L. Dahut, J.L. Gulley, P.M. Arlen, Y. Liu, K.M. Fedenko, S.M. Steinberg Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 2004 2532 2539
24. G.J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
25. M.K. Horne III, W.D. Figg, P. Arlen, J. Gulley, C. Parker, N. Lakhani Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer Pharmacotherapy 23 2003 315 318
26. S.M. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, J.A. Goldstein The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 1994 15419 15422
27. J.A. Goldstein, T. Ishizaki, K. Chiba, S.M. de Morais, D. Bell, P.M. Krahn Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations Pharmacogenetics 7 1997 59 64